Home » Stocks » PFNX

Pfenex Inc. (PFNX)

Sep 30, 2020 - PFNX was delisted after being acquired by LGND
Stock Price: $12.75 USD 0.00 (0.00%)
Updated Sep 30, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 437.28M
Revenue (ttm) 38.62M
Net Income (ttm) -8.13M
Shares Out 34.30M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE 42.37
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 30, 2020
Last Price $12.75
Previous Close $12.75
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 12.74 - 12.94
Day's Volume 0
52-Week Range 5.26 - 14.00

More Stats

Market Cap 437.28M
Enterprise Value 379.38M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 34.30M
Float 34.15M
EPS (basic) -0.22
EPS (diluted) -0.18
FCF / Share -0.16
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 539,032
Short Ratio 0.93
Short % of Float 1.58%
Beta 1.32
PE Ratio n/a
Forward PE 42.37
P/FCF Ratio n/a
PS Ratio 11.32
PB Ratio 5.90
Revenue 38.62M
Operating Income -8.28M
Net Income -8.13M
Free Cash Flow -5.54M
Net Cash 57.91M
Net Cash / Share 1.69
Gross Margin 110.50%
Operating Margin -21.43%
Profit Margin -21.10%
FCF Margin -14.34%
ROA -4.95%
ROE -9.22%
ROIC -59.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 0
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$14.67*
(15.06% upside)
Low
13.0
Current: $12.75
High
18.0
Target: 14.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue50.3314.8628.7860.199.5810.6411.9111.29
Revenue Growth238.74%-48.38%-52.19%528.13%-9.97%-10.66%5.49%-
Gross Profit45.449.8423.6254.884.943.415.494.04
Operating Income0.82-39.85-25.985.12-27.84-9.72-6.70-4.63
Net Income1.06-39.59-25.685.48-28.22-9.79-4.06-2.59
Shares Outstanding31.6028.3423.5023.3922.389.441.531.47
Earnings Per Share0.03-1.40-1.090.23-1.26-1.04-3.76-2.84
Operating Cash Flow-4.13-39.43-21.51-22.2724.23-10.00-4.60-2.89
Capital Expenditures-0.85-1.47-2.20-2.86-1.47-0.32-0.11-0.32
Free Cash Flow-4.97-40.90-23.71-25.1322.76-10.32-4.71-3.21
Cash & Equivalents55.8256.4257.8681.5011049.689.2311.47
Total Debt3.850.510.650.083.813.813.591.14
Net Cash / Debt51.9855.9157.2281.4210645.865.6410.33
Assets84.8981.2879.3910313271.0231.8132.93
Liabilities12.5920.1421.6322.9860.5111.1513.0810.29
Book Value72.3061.1457.7680.1571.1859.87-94.45-19.86
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pfenex Inc.
Country United States
Employees 88
CEO Evert B. Schimmelpennink

Stock Information

Ticker Symbol PFNX
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: PFNX
IPO Date July 24, 2014

Description

Pfenex, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidate include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis. The company also develops PF743, a recombinant crisantaspase; PF745, a recombinant crisantaspase with half-life extension technology; and PF810, a peptide based next generation therapeutic which is in preclinical development, as well as offers sparX-1 (PF753) and sparX-2 (PF754). In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.